|
1
|
Price TJ, Peeters M, Kim TW, Li J, Cascinu
S, Ruff P, Suresh AS, Thomas A, Tjulandin S, Zhang K, et al:
Panitumumab versus cetuximab in patients with
chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal
cancer (ASPECCT): A randomised, multicentre, open-label,
non-inferiority phase 3 study. Lancet Oncol. 15:569–579. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Denis F, Lethrosne C, Pourel N, Molinier
O, Pointreau Y, Domont J, Bourgeois H, Senellart H, Trémolières P,
Lizée T, et al: Randomized Trial Comparing a Web-Mediated Follow-up
With Routine Surveillance in Lung Cancer Patients. J Natl Cancer
Inst. 109:1092017. View Article : Google Scholar
|
|
3
|
Guo Y, Sun W, Gong T, Chai Y, Wang J, Hui
B, Li Y, Song L and Gao Y: miR-30a radiosensitizes non-small cell
lung cancer by targeting ATF1 that is involved in the
phosphorylation of ATM. Oncol Rep. 37:1980–1988. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li H, Zhou H, Luo J and Huang J:
MicroRNA-17-5p inhibits proliferation and triggers apoptosis in
non-small cell lung cancer by targeting transforming growth factor
β receptor 2. Exp Ther Med. 13:2715–2722. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ju L, Han M, Li X and Zhao C: MicroRNA
signature of lung adenocarcinoma with EGFR exon 19 deletion. J
Cancer. 8:1311–1318. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li X, Liu Y, Shi W, Xu H, Hu H, Dong Z,
Zhu G, Sun Y, Liu B, Gao H, et al: Droplet digital PCR improved the
EGFR mutation diagnosis with pleural fluid samples in
non-small-cell lung cancer patients. Clin Chim Acta. 471:177–184.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ni J, Weng L, Liu Y, Sun Z, Bai C and Wang
Y: Dynamic monitoring of EGFR mutations in circulating cell-free
DNA for EGFR-mutant metastatic patients with lung cancer: Early
detection of drug resistance and prognostic significance. Oncol
Lett. 13:4549–4557. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gao JW, Zhan P, Qiu XY, Jin JJ, Lv TF and
Song Y: Erlotinib-based doublet targeted therapy versus erlotinib
alone in previously treated advanced non-small-cell lung cancer: A
meta-analysis from 24 randomized controlled trials. Oncotarget.
8:73258–73270. 2017.PubMed/NCBI
|
|
9
|
Zhou G, Zhang F, Guo Y, Huang J, Xie Y,
Yue S, Chen M, Jiang H and Li M: miR-200c enhances sensitivity of
drug-resistant non-small cell lung cancer to gefitinib by
suppression of PI3K/Akt signaling pathway and inhibites cell
migration via targeting ZEB1. Biomed Pharmacother. 85:113–119.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu XL, Zhang XT, Meng J, Zhang HF, Zhao
Y, Li C, Sun Y, Mei QB, Zhang F and Zhang T: ING5 knockdown
enhances migration and invasion of lung cancer cells by inducing
EMT via EGFR/PI3K/Akt and IL-6/STAT3 signaling pathways.
Oncotarget. 8:54265–54276. 2017.PubMed/NCBI
|
|
11
|
Tang Y, Wang Y, Chen Q, Qiu N, Zhao Y and
You X: MiR-223 inhibited cell metastasis of human cervical cancer
by modulating epithelial-mesenchymal transition. Int J Clin Exp
Pathol. 8:11224–11229. 2015.PubMed/NCBI
|
|
12
|
Soria JC, Adjei AA, Bahleda R, Besse B,
Ferte C, Planchard D, Zhou J, Ware J, Morrissey K, Shankar G, et
al: A phase IB dose-escalation study of the safety and
pharmacokinetics of pictilisib in combination with either
paclitaxel and carboplatin (with or without bevacizumab) or
pemetrexed and cisplatin (with or without bevacizumab) in patients
with advanced non-small cell lung cancer. Eur J Cancer. 86:186–196.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wakelee HA, Dahlberg SE, Keller SM, Tester
WJ, Gandara DR, Graziano SL, Adjei AA, Leighl NB, Aisner SC,
Rothman JM, et al: ECOG-ACRIN: Adjuvant chemotherapy with or
without bevacizumab in patients with resected non-small-cell lung
cancer (E1505): An open-label, multicentre, randomised, phase 3
trial. Lancet Oncol. 18:1610–1623. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Melichar B, Adenis A, Lockhart AC,
Bennouna J, Dees EC, Kayaleh O, Obermannova R, DeMichele A,
Zatloukal P, Zhang B, et al: Safety and activity of alisertib, an
investigational aurora kinase A inhibitor, in patients with breast
cancer, small-cell lung cancer, non-small-cell lung cancer, head
and neck squamous-cell carcinoma, and gastro-oesophageal
adenocarcinoma: A five-arm phase 2 study. Lancet Oncol. 16:395–405.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schofield P, Ugalde A, Gough K, Reece J,
Krishnasamy M, Carey M, Ball D and Aranda S: A tailored, supportive
care intervention using systematic assessment designed for people
with inoperable lung cancer: A randomised controlled trial.
Psychooncology. 22:2445–2453. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schuette W, Behringer D, Stoehlmacher J,
Kollmeier J, Schmager S, Fischer von Weikersthal L, Schumann C and
Buchmann J: CHAMP: A phase II study of panitumumab with pemetrexed
and cisplatin versus pemetrexed and cisplatin in the treatment of
patients with advanced-stage primary nonsquamous non-small-cell
lung cancer with particular regard to the KRAS status. Clin Lung
Cancer. 16:447–456. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhou W, Ye XL, Xu J, Cao MG, Fang ZY, Li
LY, Guan GH, Liu Q, Qian YH and Xie D: The lncRNA H19 mediates
breast cancer cell plasticity during EMT and MET plasticity by
differentially sponging miR-200b/c and let-7b. Sci Signal.
10:102017. View Article : Google Scholar
|
|
18
|
Daly C, Castanaro C, Zhang W, Zhang Q, Wei
Y, Ni M, Young TM, Zhang L, Burova E and Thurston G: FGFR3-TACC3
fusion proteins act as naturally occurring drivers of tumor
resistance by functionally substituting for EGFR/ERK signaling.
Oncogene. 36:471–481. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim JY, Welsh EA, Fang B, Bai Y, Kinose F,
Eschrich SA, Koomen JM and Haura EB: Phosphoproteomics reveals MAPK
inhibitors enhance MET- and EGFR-driven AKT signaling in
KRAS-mutant lung cancer. Mol Cancer Res. 14:1019–1029. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pan H, Jiang T, Cheng N, Wang Q, Ren S, Li
X, Zhao C, Zhang L, Cai W and Zhou C: Long non-coding RNA BC087858
induces non-T790M mutation acquired resistance to EGFR-TKIs by
activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell
lung cancer. Oncotarget. 7:49948–49960. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Torres AF, Nogueira C, Magalhaes J, Costa
IS, Aragao A, Gomes Neto A, Martins F and Tavora F: Expression of
EGFR and molecules downstream to PI3K/Akt, Raf-1-MEK-1-MAP
(Erk1/2), and JAK (STAT3) pathways in invasive lung adenocarcinomas
resected at a single institution. Anal Cell Pathol (Amst) 2014.
3529252014.
|
|
22
|
Li H, Schmid-Bindert G, Wang D, Zhao Y,
Yang X, Su B and Zhou C: Blocking the PI3K/AKT and MEK/ERK
signaling pathways can overcome gefitinib-resistance in non-small
cell lung cancer cell lines. Adv Med Sci. 56:275–284. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Q, Zhao DY, Xu H, Zhou H, Yang QY,
Liu F and Zhou GP: Down-regulation of microRNA-223 promotes
degranulation via the PI3K/Akt pathway by targeting IGF-1R in mast
cells. PLoS One. 10:e01235752015. View Article : Google Scholar : PubMed/NCBI
|
